Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis

2004 ◽  
Vol 87 (1) ◽  
pp. 46-52 ◽  
Author(s):  
Andrea Gardini ◽  
Giorgio Ercolani ◽  
Angela Riccobon ◽  
Matteo Ravaioli ◽  
Laura Ridolfi ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Hepatic Resection ◽  
Adoptive Immunotherapy ◽  
Colorectal Liver Metastases ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

Liver Metastases from Gastric Carcinoma: Report of a Patient Treated with Adoptive Immunotherapy (Tumor-Infiltrating Lymphocytes plus Interleukin-2 and Subsequently Local-Regional Lymphokine-Activated Killer Cells plus inTerleukin-2)

1995 ◽  
Vol 81 (6) ◽  
pp. 445-449 ◽  
Author(s):  
Laura Fabbri ◽  
Ruggero Ridolfi ◽  
Angela Riccobon ◽  
Roberta Maltoni ◽  
Emanuela Flamini ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Liver Metastases ◽  
Adoptive Immunotherapy ◽  
Specific Activity ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Lymphokine Activated Killer Cells ◽  
Killer Cells ◽  
Infiltrating Lymphocytes

A 37-year-old patient with liver metastases from gastric cancer was treated with a double adoptive immunotherapy regimen comprising tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2 because of an extremely high in vitro cytotoxic specific activity on established gastric cancer cell lines. The necrosis verified in the center of the hepatic metastasis would appear to demonstrate treatment efficacy, but no clinical response was seen. In vitro cytotoxicity data alone are insufficient to predict the clinical efficacy of adoptive immunotherapy.

Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.

1995 ◽  
Vol 13 (2) ◽  
pp. 410-418 ◽  
Author(s):  
Y Merrouche ◽  
S Negrier ◽  
C Bain ◽  
V Combaret ◽  
A Mercatello ◽  
...  
Keyword(s):  
Adoptive Immunotherapy ◽  
Human Lymphocytes ◽  
Marker Gene ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Pcr Analysis ◽  
Gene Marker ◽  
Gene Transduction ◽  
Infiltrating Lymphocytes

PURPOSE Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and interleukin-2 (IL-2) has been reported to mediate tumor regression in some human cancers. To define better the biologic characteristics of TIL, especially survival and distribution in vivo, we performed a gene-marker study in patients with advanced malignancies. PATIENTS AND METHODS We treated five patients with metastatic melanoma or renal cell carcinoma with adoptive immunotherapy. TIL were genetically modified, before their infusion, using a recombinant retroviral vector that contained the marker gene coding for resistance to neomycin (NeoR). RESULTS All of the patients tolerated the treatment well and none of the theoretic safety hazards due to the retroviral gene transduction was observed. The presence of the NeoR gene in TIL was detected by Southern blot analysis, with an efficiency of transduction that ranged from 1% to 26%. With polymerase chain reaction (PCR) analysis, we demonstrated that gene-modified TIL can survive for several months after reinjection, since positive blood samples were observed up to day 260 following reinjection. Eight malignant biopsy specimens were obtained from three patients after cell infusion. TIL were detected in only four of these eight tumor deposits on days 7 and 260. CONCLUSION These results confirm the feasibility and safety of using in vitro retroviral gene transduction in human lymphocytes to analyze their in vivo distribution for further therapeutic applications. However, a selective and prolonged retention of TIL at the tumor site was not found in this study.

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

1988 ◽  
Vol 6 (5) ◽  
pp. 839-853 ◽  
Author(s):  
S L Topalian ◽  
D Solomon ◽  
F P Avis ◽  
A E Chang ◽  
D L Freerksen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Advanced Cancer ◽  
Adoptive Immunotherapy ◽  
Renal Cell ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Lak Cells ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

Clinical investigations using the adoptive transfer of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) to treat patients with advanced cancer have yielded encouraging results. We have thus sought ways to enhance the effectiveness of adoptive immunotherapy while minimizing its toxic side effects. Murine experiments have identified tumor-infiltrating lymphocytes (TIL) as killer cells more effective than LAK cells and less dependent on adjunctive systemically administered IL-2 to mediate antitumor effects. Accordingly, we performed a pilot protocol to investigate the feasibility and practicality of administering IL-2-expanded TIL to humans with metastatic cancers. Twelve patients, including six with melanoma, four with renal cell carcinoma, one with breast carcinoma, and one with colon carcinoma, were treated with varying doses and combinations of TIL (8.0 X 10(9) to 2.3 X 10(11) cells per patient), IL-2 (10,000 to 100,000 U/kg three times daily to dose-limiting toxicity), and cyclophosphamide (CPM) (up to 50 mg/kg). Two partial responses (PR) to therapy were observed: pulmonary and mediastinal masses regressed in a patient with melanoma, and a lymph node mass regressed in a patient with renal cell carcinoma. One additional patient with breast cancer experienced a partial regression of disease in lymph nodal and cutaneous sites with complete elimination of malignant cells from a pleural effusion, although cutaneous disease recurred at 4 weeks. The toxicities of therapy were similar to those ascribed to IL-2; no toxic effects were directly attributable to TIL infusions. In five of six melanoma patients, TIL demonstrated lytic activity specific for the autologous tumor target in short-term chromium-release assays, distinct from the nonspecific lytic activity characteristic of LAK cells. This study represents an initial attempt to identify and use lymphocyte subsets with enhanced tumoricidal capacity in the adoptive immunotherapy of human malignancies.

Intraperitoneal Adoptive Immunotherapy of Ovarian Carcinoma with Tumor-Infiltrating Lymphocytes and Low-Dose Recombinant Interleukin-2

1994 ◽  
Vol 16 (3) ◽  
pp. 198-210 ◽  
Author(s):  
Ralph S. Freedman ◽  
Creighton L. Edwards ◽  
John J. Kavanagh ◽  
Andrzej P. Kudelka ◽  
Ruth L. Katz ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Adoptive Immunotherapy ◽  
Low Dose ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Recombinant Interleukin 2 ◽  
Infiltrating Lymphocytes

Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy

1994 ◽  
Vol 167 (1-2) ◽  
pp. 145-160 ◽  
Author(s):  
Ralph S. Freedman ◽  
Barbara Tomasovic ◽  
Stacie Templin ◽  
Edward N. Atkinson ◽  
Andrzej Kudelka ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Adoptive Immunotherapy ◽  
Large Scale ◽  
Interleukin 2 ◽  
Tumor Infiltrating Lymphocytes ◽  
Scale Expansion ◽  
Infiltrating Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document